Explore News By Topic


PCF-Funded Research Inhibits Prostate Cancer Growth

New research, just published in Cancer Discovery, describes a new therapy with promising preclinical activity that is now being tested in clinical trials for very advanced prostate cancer patients. Early studies suggest this treatment has promising activity for the significant proportion of patients with advanced prostate cancer whose tumors remain... Read More


Breaking News: FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer

On Friday, December 18, 2020, the US FDA approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, for adult patients with advanced prostate cancer. This is an important advance because it offers another option to patients who are taking hormone therapy. One of the mainstays of treatment for high-risk... Read More


New Recommendations Offer Guidance for Clinicians & Patients on Implementing Genetic Testing for Prostate Cancer

PHILADELPHIA — An international panel of experts led by researchers and thought-leaders at the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and the Department of Urology at Jefferson have published the first multidisciplinary, consensus-driven prostate cancer genetic implementation framework for the precision medicine era. The consensus framework is a... Read More


Major Trial Shows Breast Cancer Drug Can Hit Prostate Cancer Achilles Heel

Olaparib, licensed for breast and ovarian cancer, is effective for some men with prostate cancer too Drug better than targeted hormone therapy in cancers with weaknesses in repairing their DNA Major clinical trial heralds approval as first gene-targeted drug in prostate cancer A drug already licensed for the treatment of... Read More


Researchers Discover How a Gene Deletion Contributes to Prostate Cancer Growth

Original Press Release Issued by: Weill Cornell Medicine The deletion of a gene that normally promotes healthy cell division in the prostate encourages the growth of cancer in the gland, according to a new study by Weill Cornell Medicine investigators. The findings, published March 28 in Cancer Cell, suggest that... Read More


New Study Identifies Another Opportunity for Precision Immunotherapy in Prostate Cancer

A new Prostate Cancer Foundation (PCF)-funded study published today in the scientific journal Cell has identified a new subtype of advanced prostate cancer – one which may be treatable with checkpoint immunotherapy, a type of treatment that can produce long-term remissions and even cures in many cancer types, but has... Read More


New and More Sensitive Prostate Cancer Imaging on the Near Horizon

At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, promising results were reported from a phase 2/3 clinical trial testing the accuracy of a new prostate cancer imaging method -- PSMA-PET -- for detecting sites of prostate cancer recurrence. The current standard imaging methods for detecting recurrent or... Read More


PCF-funded investigators report progress on a promising new treatment for a highly lethal form of prostate cancer

Prostate cancer cells depend on androgens to grow and thrive.  Because of this dependency, hormone therapy – the blockade of androgens and the androgen receptor (AR) – has been the cornerstone of prostate cancer treatment for decades.  As science has progressed, therapies that are better and better at blocking these... Read More


Scientists uncover “long tail” of nearly 100 genes mutated in prostate cancer

APRIL 2, 2018 --  Issued by Dana-Farber Cancer Institute. By sequencing DNA in more than 1,000 patient samples, researchers have identified a total of 97 genes significantly mutated in prostate cancer, including 70 not previously implicated in the disease. The large-scale study identified a new class of prostate cancers defined... Read More


New Study indicates 18 months of androgen deprivation therapy may be optimal for locally advanced prostate cancer

Results from the RADAR clinical trial presented at the 2018 ASCO Genitourinary Cancer Symposium indicate that 18 months of ADT could very likely become the new standard of care. The RADAR trial demonstrated that 18 months of androgen deprivation therapy (ADT) is significantly better than 6 months of ADT at... Read More